Omeros Corporation (NASDAQ:OMER) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Omeros Corporation (NASDAQ:OMER) have earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $33.6667.

OMER has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating on shares of Omeros in a research note on Wednesday, December 24th. D. Boral Capital restated a “buy” rating and set a $36.00 target price on shares of Omeros in a research report on Wednesday, December 24th. Wall Street Zen raised Omeros from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a report on Wednesday, October 8th.

Omeros Stock Up 1.2%

NASDAQ OMER opened at $17.17 on Friday. The company has a market cap of $1.22 billion, a PE ratio of -8.50 and a beta of 2.37. Omeros has a 52 week low of $2.95 and a 52 week high of $17.65. The firm’s 50-day simple moving average is $9.79 and its two-hundred day simple moving average is $6.18.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.39. As a group, equities research analysts anticipate that Omeros will post -3.09 EPS for the current year.

Hedge Funds Weigh In On Omeros

A number of large investors have recently modified their holdings of OMER. Vanguard Group Inc. grew its stake in Omeros by 1.9% during the third quarter. Vanguard Group Inc. now owns 3,346,958 shares of the biopharmaceutical company’s stock valued at $13,723,000 after acquiring an additional 63,381 shares in the last quarter. Two Sigma Investments LP grew its position in shares of Omeros by 39.3% during the 3rd quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock valued at $3,827,000 after purchasing an additional 263,095 shares in the last quarter. Marshall Wace LLP grew its position in shares of Omeros by 15.1% during the 2nd quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock valued at $2,224,000 after purchasing an additional 97,224 shares in the last quarter. Bank of Montreal Can increased its holdings in shares of Omeros by 1.4% in the second quarter. Bank of Montreal Can now owns 571,095 shares of the biopharmaceutical company’s stock worth $1,713,000 after purchasing an additional 8,000 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of Omeros by 1,201.1% in the third quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock worth $1,706,000 after buying an additional 384,168 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.